Browse studies

Find your next paid study

27,300 recruiting studies available now

Intraoperative Optical Coherence Tomography - Normals

Optical Coherence Tomography (OCT) image data will be evaluated for image quality and used to test post-processing algorithms to improve detection sensitivity …

Healthy Volunteers

Estimated

~$10 – $750

Actual pay is set by the research site.

Vanderbilt University Medical CenterNCT04790890

Phase 2

A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis

The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.

Primary Hyperoxaluria Type 1End Stage Renal Disease

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyNCT04580420

Phase 2

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

The purpose of this study is to see if the combination of rituximab and venetoclax is effective in treating participants with untreated Marginal Zone Lymphoma …

LymphomaMarginal Zone LymphomaMZL

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Gottfried von Keudell, MD PhDNCT06510309

Natural History Study of Parathyroid Disorders

Background: Parathyroid disorders are very common in the general population and include disorders of parathyroid excess, deficiency, or defects in parathyroid…

Parathyroid CancerPrimary HyperparathyroidismPseudohypoparathyroidism+2 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT04969926

Phase 2

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and chi…

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Relay Therapeutics, Inc.NCT06789913

Phase 2

A Phase II, Single-arm, Multi-center, Open-label Study of Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as an Induction Immunotherapy for Stage II/III TNBC Patients

This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.

Triple Negative Breast Cancer

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Providence Health & ServicesNCT06353997

Phase 1

Evaluation of Multiple Alkalinizing Agents on Urinary Stone Risk Parameters in Stone and Non-stone Formers on a Metabolically Controlled Diet

The purpose of this study is to compare over the counter and alternative prescription urinary alkalinizing agents to slow release potassium citrate in their ab…

Kidney Stone

Estimated

~$500 – $7,500

Actual pay is set by the research site.

University of Texas Southwestern Medical CenterNCT04651088

Evaluation of Wearable Sensor-Based Estimation of Left Ventricular Ejection Fraction (LVEF) - Pilot Study

The goal of this study is to develop a wearable sensor system that can estimate left ventricular ejection fraction (LVEF), which is a measurement of the heart'…

CardiotoxicityHeart Failure

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Skribe MedicalNCT07158450

Phase 1

Impact of BPC-157 on Recovery From Rotator Cuff Repair Surgery

This study is a randomized, double-blind, placebo-controlled pilot trial investigating the effects of BPC-157 on tendon healing and functional recovery followi…

Rotator Cuff Tear

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of ArkansasNCT07803250

Observational

Effects of Diet Data Return on Human Dietary Patterns

This study is designed to test the effects of diet data return on human dietary patterns. The investigators' working hypothesis is that returning diet data, co…

Diet Habit

Estimated

~$10 – $750

Actual pay is set by the research site.

Duke UniversityNCT06266689

Phase 2

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen re…

Metastatic Castration-Resistant Prostate Cancer

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Hoffmann-La RocheNCT07287150

Phase 3

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homol…

Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaFallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor+9 more

Estimated

~$50 – $2,250

Actual pay is set by the research site.